- Home
- NCTY vs NKTX Comparison
NCTY vs NKTX Comparison
Compare NCTY & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- NKTX
- Stock Information
- Founded
- NCTY 1999
- NKTX 2015
- Country
- NCTY China
- NKTX United States
- Employees
- NCTY N/A
- NKTX N/A
- Industry
- NCTY Business Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- NKTX Health Care
- Exchange
- NCTY Nasdaq
- NKTX Nasdaq
- Market Cap
- NCTY 121.2M
- NKTX 123.5M
- IPO Year
- NCTY 2004
- NKTX 2020
- Fundamental
- Price
- NCTY $10.02
- NKTX $1.91
- Analyst Decision
- NCTY
- NKTX Strong Buy
- Analyst Count
- NCTY 0
- NKTX 5
- Target Price
- NCTY N/A
- NKTX $13.50
- AVG Volume (30 Days)
- NCTY 57.4K
- NKTX 489.9K
- Earning Date
- NCTY 01-01-0001
- NKTX 11-06-2025
- Dividend Yield
- NCTY N/A
- NKTX N/A
- EPS Growth
- NCTY N/A
- NKTX N/A
- EPS
- NCTY N/A
- NKTX N/A
- Revenue
- NCTY $15,305,175.00
- NKTX N/A
- Revenue This Year
- NCTY N/A
- NKTX N/A
- Revenue Next Year
- NCTY N/A
- NKTX N/A
- P/E Ratio
- NCTY N/A
- NKTX N/A
- Revenue Growth
- NCTY N/A
- NKTX N/A
- 52 Week Low
- NCTY $6.28
- NKTX $1.31
- 52 Week High
- NCTY $20.59
- NKTX $5.83
- Technical
- Relative Strength Index (RSI)
- NCTY 55.26
- NKTX 38.03
- Support Level
- NCTY $9.06
- NKTX $2.00
- Resistance Level
- NCTY $11.20
- NKTX $2.08
- Average True Range (ATR)
- NCTY 0.73
- NKTX 0.11
- MACD
- NCTY 0.13
- NKTX -0.03
- Stochastic Oscillator
- NCTY 55.13
- NKTX 0.00
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.